Traws Pharma (TRAW) EBIAT (2016 - 2025)
Historic EBIAT for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$4.0 million.
- Traws Pharma's EBIAT rose 5325.07% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.3 million, marking a year-over-year increase of 9054.66%. This contributed to the annual value of -$166.5 million for FY2024, which is 77884.21% down from last year.
- Per Traws Pharma's latest filing, its EBIAT stood at -$4.0 million for Q3 2025, which was up 5325.07% from -$915000.0 recorded in Q2 2025.
- Traws Pharma's 5-year EBIAT high stood at $21.5 million for Q1 2025, and its period low was -$123.1 million during Q2 2024.
- For the 5-year period, Traws Pharma's EBIAT averaged around -$10.7 million, with its median value being -$4.2 million (2023).
- Per our database at Business Quant, Traws Pharma's EBIAT tumbled by 279748.24% in 2024 and then soared by 53126.63% in 2025.
- Traws Pharma's EBIAT (Quarter) stood at -$3.8 million in 2021, then plummeted by 44.0% to -$5.4 million in 2022, then increased by 22.8% to -$4.2 million in 2023, then plummeted by 615.15% to -$29.9 million in 2024, then surged by 86.76% to -$4.0 million in 2025.
- Its EBIAT was -$4.0 million in Q3 2025, compared to -$915000.0 in Q2 2025 and $21.5 million in Q1 2025.